Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05119790 · ClinicalTrials.gov registry record · Phase 1
A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT05119790 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 7 participants.
The verdict
NCT05119790, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a single-center, non-randomized, open-label Phase 1 study to determine the absorption, metabolism, and excretion (AME) of BIIB122 (DNL151) following administration of a single oral dose of \[14C\] BIIB122 (\[14C\] DNL151) following a fast. The mass balance, excretion, and PK of BIIB122 (DNL151) will be used to evaluate AME.
Interventions
- DRUG [14C] BIIB122 ([14C] DNL151)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-08-27 |
| Est. Completion | 2021-11-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05119790
The ClinicalTrials.gov registry entry for NCT05119790 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [14C] BIIB122 ([14C] DNL151) is the first listed.
NCT05119790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05119790 about?
NCT05119790 is a clinical study titled "A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects". This is a single-center, non-randomized, open-label Phase 1 study to determine the absorption, metabolism, and excretion (AME) of BIIB122 (DNL151) following administration of a single oral dose of \[14C\] BIIB122 (\[14C\] DNL151) following a fast. The mass balance, excretion, and PK of BIIB122 (DNL1...
What is the current status of trial NCT05119790?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2021-08-27. Estimated completion is 2021-11-05.
What interventions are being tested in trial NCT05119790?
The interventions under investigation include: [14C] BIIB122 ([14C] DNL151) (DRUG).
Who is sponsoring clinical trial NCT05119790?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.